At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
Crizanlizumabdrug
Likely dose
Crizanlizumab 10 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
In Brief
A Phase 2 clinical trial evaluating Crizanlizumab for Priapism. Completed, enrolled 36 participants across 13 sites.
Detailed Summary
The goal of the study was to evaluate the efficacy and safety of crizanlizumab in sickle cell disease (SCD) patients with priapism.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPriapism
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartOct 2019
Primary CompletionMar 2023
Study CompletionNov 2023
TodayJul 2026
First PostedMay 6, 2019
Enrollment StartOct 16, 2019
Primary CompletionMar 28, 2023
Study CompletionNov 29, 2023
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 7.2 years ago
Interventions
Crizanlizumabdrug
Crizanlizumab is a concentrate for solution for infusion, IV use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.